As filed with the Securities and Exchange Commission on June 11, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Avidity Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 2834 | 46-1336960 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
10975 N. Torrey Pines Road, Suite 150
La Jolla, California 92037
(858) 401-7900
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Sarah Boyce
President and Chief Executive Officer
Avidity Biosciences, Inc.
10975 N. Torrey Pines Road, Suite 150
La Jolla, California 92037
(858) 401-7900
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
Copies to:
Matthew T. Bush Cheston J. Larson Alaina P. Ellis Latham & Watkins LLP 12670 High Bluff Drive San Diego, California 92130 (858) 523-5400 |
Richard C. Segal Charles S. Kim Divakar Gupta Will H. Cai Cooley LLP 4401 Eastgate Mall San Diego, California 92121 (858) 550-6000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-238612)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definition of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ |
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Each Class of Securities to be Registered | Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering |
Amount of Registration Fee(2)(3) | ||||
Common stock, $0.0001 par value per share |
2,760,000 | $18.00 | $49,680,000 | $6,449 | ||||
| ||||||||
|
(1) | Represents only the additional number of shares being registered and includes 360,000 additional shares of common stock that the underwriters have the option to purchase. This does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1, as amended (File No. 333-238612) (Prior Registration Statement). |
(2) | Calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended. |
(3) | The Registrant previously registered 13,800,000 shares of its common stock with an aggregate offering price not to exceed $248,400,000 on the Prior Registration Statement, which was declared effective by the Securities and Exchange Commission on June 11, 2020. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $49,680,000 are hereby registered, which includes shares that the underwriters have the option to purchase. |
The Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement on Form S-1 (this Registration Statement) is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the sole purpose of increasing the aggregate number of shares of common stock offered by Avidity Biosciences, Inc. (the Registrant) by 2,760,000 shares, 360,000 of which are subject to purchase upon exercise of the underwriters option to purchase additional shares of the Registrants common stock. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Registration Statement on Form S-1, as amended (File No. 333-238612) (the Prior Registration Statement). The information set forth in the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference in this filing.
The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on this 11th day of June, 2020.
AVIDITY BIOSCIENCES, INC. | ||
By: |
/s/ Sarah Boyce | |
Sarah Boyce | ||
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.
Signature |
Title |
Date | ||
/s/ Sarah Boyce Sarah Boyce |
President, Chief Executive Officer and Director (principal executive officer) |
June 11, 2020 | ||
/s/ Michael F. MacLean Michael F. MacLean |
Chief Financial Officer (principal financial and accounting officer) |
June 11, 2020 | ||
* Troy Wilson, Ph.D., J.D. |
Executive Chairman of the Board of Directors | June 11, 2020 | ||
* Carsten Boess |
Director | June 11, 2020 | ||
* Todd Brady |
Director | June 11, 2020 | ||
* Noreen Henig, M.D. |
Director | June 11, 2020 | ||
* Edward Kaye, M.D. |
Director | June 11, 2020 | ||
* Michael Martin, Ph.D. |
Director | June 11, 2020 | ||
* Roderick Wong, M.D. |
Director | June 11, 2020 |
*By: | /s/ Sarah Boyce | |||
Sarah Boyce | ||||
Attorney-in-fact |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Avidity Biosciences, Inc.
San Diego, California
We hereby consent to the incorporation by reference in this Registration Statement of our report dated April 3, 2020 (except for the Reverse Stock Split paragraph of Note 11, as to which the date is June 8, 2020), relating to the financial statements of Avidity Biosciences, Inc. (the Company), which is included in the Companys Registration Statement on Form S-1 (no. 333-238612), as amended.
We also consent to the reference to us under the heading Experts in the Registration Statement on Form S-1 (no. 333-238612), as amended, incorporated by reference in this Registration Statement.
/s/ BDO USA, LLP
San Diego, California
June 11, 2020